{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:30:55Z","timestamp":1789421455922,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11239-017-1566-1","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T04:20:51Z","timestamp":1507695651000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation"],"prefix":"10.1007","volume":"45","author":[{"given":"Roberto","family":"Castelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallipoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Teatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Lambertenghi","family":"Deliliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Bergamaschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"1566_CR1","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20132232. doi: 10.1200\/JCO.2005.07.062","journal-title":"J Clin Oncol"},{"key":"1566_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.leukres.2015.03.009","volume":"39","author":"U Gianelli","year":"2015","unstructured":"Gianelli U, Iurlo A, Cattaneo D et al (2015) Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leuk Res 39:525\u2013529. doi: 10.1016\/j.leukres.2015.03.009","journal-title":"Leuk Res"},{"key":"1566_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18. doi: 10.1186\/s13045-016-0242-9","journal-title":"J Hematol Oncol"},{"key":"1566_CR4","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J et al (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121:1720\u20131728. doi: 10.1182\/blood-2012-07-443770","journal-title":"Blood"},{"key":"1566_CR5","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20132232. doi: 10.1200\/JCO.2005.07.062","journal-title":"J Clin Oncol"},{"key":"1566_CR6","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:5857\u20135859. doi: 10.1182\/blood-2011-02-339002","journal-title":"Blood"},{"key":"1566_CR7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/157488809788167445","volume":"4","author":"E Spanoudakis","year":"2009","unstructured":"Spanoudakis E, Tsatalas C (2009) Hemopoiesis in Ph-negative chronic myeloproliferative disorders. Curr Stem Cell Res Ther 4:154\u2013160","journal-title":"Curr Stem Cell Res Ther"},{"key":"1566_CR8","first-page":"394","volume":"30","author":"G-Y Hu","year":"2009","unstructured":"Hu G-Y, Deng M-Y, Zhang G-S et al (2009) The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK\/STATs proteins and their clinical significance in myeloproliferative disorders patients. Zhonghua Xue Ye Xue Za Zhi 30:394\u2013398","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"1566_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3324\/haematol.2012.076901","volume":"98","author":"T Lange","year":"2013","unstructured":"Lange T, Edelmann A, Siebolts U et al (2013) JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 98:722\u2013728. doi: 10.3324\/haematol.2012.076901","journal-title":"Haematologica"},{"key":"1566_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2008.001271","volume":"94","author":"F Passamonti","year":"2009","unstructured":"Passamonti F, Rumi E (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 94:7\u201310. doi: 10.3324\/haematol.2008.001271","journal-title":"Haematologica"},{"key":"1566_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3324\/haematol.11653","volume":"93","author":"E Antonioli","year":"2008","unstructured":"Antonioli E, Guglielmelli P, Poli G et al (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93:41\u201348. doi: 10.3324\/haematol.11653","journal-title":"Haematologica"},{"key":"1566_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11899-009-0038-x","volume":"5","author":"AM Vannucchi","year":"2010","unstructured":"Vannucchi AM (2010) JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Curr Hematol Malig Rep 5:22\u201328. doi: 10.1007\/s11899-009-0038-x","journal-title":"Curr Hematol Malig Rep"},{"key":"1566_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14102","author":"M Scully","year":"2016","unstructured":"Scully M, Gates C, Neave L (2016) How we manage patients with heparin induced thrombocytopenia. Br J Haematol. doi: 10.1111\/bjh.14102","journal-title":"Br J Haematol"},{"key":"1566_CR14","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C et al (2014) Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124:1062\u20131069. doi: 10.1182\/blood-2014-05-578435","journal-title":"Blood"},{"key":"1566_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","volume":"96","author":"I Bertozzi","year":"2017","unstructured":"Bertozzi I, Bogoni G, Biagetti G et al (2017) Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol 96:1297\u20131302. doi: 10.1007\/s00277-017-3040-8","journal-title":"Ann Hematol"},{"key":"1566_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ajh.24607","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Barbui T (2017) Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 92:94\u2013108. doi: 10.1002\/ajh.24607","journal-title":"Am J Hematol"},{"key":"1566_CR17","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D et al (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24:1574\u20131579. doi: 10.1038\/leu.2010.148","journal-title":"Leukemia"},{"key":"1566_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer PA, Campbell PJ, Scott LM et al (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112:141\u2013149. doi: 10.1182\/blood-2008-01-131664","journal-title":"Blood"},{"key":"1566_CR19","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u20132390. doi: 10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"key":"1566_CR20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-539098","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. doi: 10.1182\/blood-2013-11-539098","journal-title":"Blood"},{"key":"1566_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/asheducation-2011.1.143","volume":"2011","author":"TE Warkentin","year":"2011","unstructured":"Warkentin TE (2011) How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Progr 2011:143\u2013149. doi: 10.1182\/asheducation-2011.1.143","journal-title":"Hematology Am Soc Hematol Educ Progr"},{"key":"1566_CR22","doi-asserted-by":"publisher","unstructured":"Warkentin TE, Aird WC, Rand JH (2003) Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Progr 497\u2013519. doi: 10.1182\/asheducation-2003.1.497","DOI":"10.1182\/asheducation-2003.1.497"},{"key":"1566_CR23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/187152907781745251","volume":"7","author":"R Castelli","year":"2007","unstructured":"Castelli R, Cassinerio E, Cappellini MD et al (2007) Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects. Cardiovasc Hematol Disord Drug Targets 7:153\u2013162","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"1566_CR24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/CCO.0b013e32834bb867","volume":"23","author":"T Barbui","year":"2011","unstructured":"Barbui T (2011) How to manage thrombosis in myeloproliferative neoplasms. Curr Opin Oncol 23:654\u2013658. doi: 10.1097\/CCO.0b013e32834bb867","journal-title":"Curr Opin Oncol"},{"key":"1566_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13874","author":"J Bovet","year":"2015","unstructured":"Bovet J, De Maistre E, Bejot Y, Girodon F (2015) Are Myeloproliferative neoplasms a risk factor for Heparin-Induced Thrombocytopenia? Br J Haematol. doi: 10.1111\/bjh.13874","journal-title":"Br J Haematol"},{"key":"1566_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MBC.0b013e32832f2b08","volume":"21","author":"M Lapecorella","year":"2010","unstructured":"Lapecorella M, Lucchesi A, Di Ianni M et al (2010) Unusual onset of venous thromboembolism and heparin-induced thrombocytopenia in a patient with essential thrombocythemia. Blood Coagul Fibrinolysis 21:85\u201390. doi: 10.1097\/MBC.0b013e32832f2b08","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1566_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000280466","volume":"123","author":"ML Randi","year":"2010","unstructured":"Randi ML, Tezza F, Scapin M et al (2010) Heparin-induced thrombocytopenia in patients with philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol 123:140\u2013145. doi: 10.1159\/000280466","journal-title":"Acta Haematol"},{"key":"1566_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14\u201322. doi: 10.1038\/sj.leu.2404955","journal-title":"Leukemia"},{"key":"1566_CR29","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","volume":"108","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Baxter EJ, Beer PA et al (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548\u20133555. doi: 10.1182\/blood-2005-12-013748","journal-title":"Blood"},{"key":"1566_CR30","doi-asserted-by":"crossref","unstructured":"Pancrazzi A, Guglielmelli P, Ponziani V et al (2008) A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn 10:435\u2013441. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18669880","DOI":"10.2353\/jmoldx.2008.080015"},{"key":"1566_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","volume":"4","author":"GK Lo","year":"2006","unstructured":"Lo GK, Juhl D, Warkentin TE et al (2006) Evaluation of pretest clinical score (4 T\u2019s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759\u2013765. doi: 10.1111\/j.1538-7836.2006.01787.x","journal-title":"J Thromb Haemost"},{"key":"1566_CR32","doi-asserted-by":"publisher","unstructured":"Prandoni P, Siragusa S, Girolami B, Fabris F The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. doi: 10.1182\/blood-2005-03-0912","DOI":"10.1182\/blood-2005-03-0912"},{"key":"1566_CR33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0037-1614536","volume":"81","author":"P Eichler","year":"1999","unstructured":"Eichler P, Budde U, Haas S et al (1999) First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4\/heparin ELISA. Thromb Haemost 81:625\u2013629","journal-title":"Thromb Haemost"},{"key":"1566_CR34","doi-asserted-by":"crossref","first-page":"146S","DOI":"10.1592\/phco.24.12.146S.36107","volume":"24","author":"CS Niccolai","year":"2004","unstructured":"Niccolai CS, Hicks RW, Oertel L et al (2004) Unfractionated heparin: focus on a high-alert drug. Pharmacotherapy 24:146S\u2013155S","journal-title":"Pharmacotherapy"},{"key":"1566_CR35","doi-asserted-by":"publisher","first-page":"311S","DOI":"10.1378\/chest.126.3_suppl.311S","volume":"126","author":"TE Warkentin","year":"2004","unstructured":"Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 126:311S\u2013337S. doi: 10.1378\/chest.126.3_suppl.311S","journal-title":"Chest"},{"key":"1566_CR36","doi-asserted-by":"crossref","unstructured":"Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710\u20132715. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15985543","DOI":"10.1182\/blood-2005-04-1546"},{"key":"1566_CR37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/ajh.21128","volume":"83","author":"G Spectre","year":"2008","unstructured":"Spectre G, Kalish Y, Schliamser L, Varon D (2008) Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? Am J Hematol 83:420\u2013423. doi: 10.1002\/ajh.21128","journal-title":"Am J Hematol"},{"key":"1566_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMcp1411910","volume":"373","author":"A Greinacher","year":"2015","unstructured":"Greinacher A (2015) Heparin-Induced Thrombocytopenia. N Engl J Med 373:252\u2013261. doi: 10.1056\/NEJMcp1411910","journal-title":"N Engl J Med"},{"key":"1566_CR39","first-page":"249","volume":"26","author":"FW Dunn","year":"1984","unstructured":"Dunn FW, Soria C, Thomaidis A et al (1984) Interactions of platelets with standard heparin and low molecular weight fractions. Nouv Rev Fr d\u2019h\u00e9matologie 26:249\u2013253","journal-title":"Nouv Rev Fr d\u2019h\u00e9matologie"},{"key":"1566_CR40","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953. doi: 10.1016\/S0140-6736(05)67785-9","journal-title":"Lancet"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-017-1566-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-017-1566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-017-1566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T12:53:43Z","timestamp":1570193623000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-017-1566-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s11239-017-1566-1","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]}}}